He has authored over 450 peer-reviewed journal articles and book chapters. Dr. Mills has been a co-editor of Rutherford’s Vascular Surgery (7th – 9th editions) and is also a current Vascular Surgery Section Editor for UpToDate. He has been the principal investigator for over 45 clinical trials covering a wide spectrum of vascular disease with a focus on limb salvage, chronic limb threatening ischemia and diabetic foot ulcers. He is Past-President of the Peripheral Vascular Surgery Society and also served as Treasurer of the SVS (Society for Vascular Surgery), Chair of the SVS Distinguished Fellows Council, and Secretary-Treasurer of the Western Vascular Society. Dr. Mills is a previous director of the ABS, past Chair of the Vascular Surgery Board (2010-2013) and completed a 7-year term on the RRC-S (2014-21). He is also Past-President of the Association of Program Directors in Vascular Surgery (APDVS), the Rocky Mountain Vascular Society and the Western Vascular Society. Most recently, he has led the SVS PPO Committee, helping spearhead the SVS Branding Campaign. He has extensive clinical experience in multiple practice settings, including: military; VA; county; university, and private hospitals. In June 2021, he was elected the Vice President of the Society for Vascular Surgery and is its current President (2023-24).

Dr. Mills received both his BS (1977) and MD (1981) degrees cum laude from Georgetown University. He subsequently completed residency programs in General Surgery at Wilford Hall USAF Medical Center (Lackland AFB), Vascular Surgery at Oregon Health Sciences University (Portland), and a Senior Endovascular Surgery Fellowship at Texas Tech University (Lubbock). He and his wife, Margaret Schneider Mills, are the proud parents of three sons (Joseph Jr., Daniel and Andrew) and six grandchildren (Edward, Thomas, Joseph III, Lucas, Ruth and Nolan).

Prof. Belkin is currently a professor emeritus of Ophthalmology and  held  the Fox Chair of Ophthalmology in Tel-Aviv University. He is also the director of the Ophthalmic Technologies Laboratory at the university’s Eye Research Institute located at the Sheba Medical Center, Israel, and serves as senior advisor to the Singapore Eye Research Institute.

Prof. Belkin served previously as Director of Research, Development and Non-conventional Warfare Medicine in the Israel Defense Forces’ Medical Corps, was the first full-time director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and President of the Israel Society of Eye and Vision Research of which he was a founder.

Prof. Belkin, who is the author of over 300 scientific publications and holds >40 patents, received an MA in Science from Cambridge University, England, and an MD in Medicine from the Hebrew University of Jerusalem, Israel.

He was chairman of medicine, Meir Hospital, Kfar Saba, and dean of the New York State/American Program of the Sackler School of Medicine, Tel Aviv University. He has conducted research in endocrinology and metabolism, authored over 130 peer-reviewed articles and served as coordinator of several FP7 European Union-funded projects, the latest, A novel nano-technological platform for pancreatic cancer diagnosis and therapy

Prof. Shenkman is the medical director of several medical high-tech companies in Israel and he serves as the medical director of BioGenCell’s clinical study.

He graduated from Albert Einstein College of Medicine  in 1973, is board-certified in both specialties and holds the title of Clinical Associate Professor of Medicine, Division of Endocrinology, at Einstein. Dr. Martin Grajower is the vice president of the Lower New York Chapter of the American Association of Clinical Endocrinologist.  He serves on the editorial board of Endocrine Practice and Journal of Hospital Administration, is co-editor of leading scientific publications and is an endocrine consultant to Prescriber’s Newsletter. Dr. Grajower also serves on many national committees, is a fellow of the American College of Physicians and the American college of Endocrinology, is an Affiliate Physician at Columbia University College of Physicians and Surgeons and maintains a leading private practice in New York. Before advising BioGenCell he served as an Advisory Board member to Bristol-Myers Squibb.

He received his M.D. (1973) from the Hebrew University in Jerusalem and continued his studies to obtain a doctorate in biological sciences in the Faculty of Medicine in the Technion (D.Sc.; 1982). There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, USA, they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. They deciphered the mechanism of conjugation, described the general proteolytic functions of the system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease. As a post- doctoral fellow with Dr. Harvey Lodish at the M.I.T., he continued his studies on the ubiquitin system and made additional important discoveries.

Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Among the numerous prizes Ciechanover received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose). Among many academies, Prof Ciechanover is a member of the Israeli National Academy of Sciences and Humanities, The European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences (CAS; Foreign Member), the Russian Academy of Sciences (Foreign Member), and the German Academy of Sciences (Leopoldina).

Dr. Veith achieved success with his pioneering work in experimental and clinical lung transplantation. In the 1970s and 1980s, Dr. Veith’s attention turned toward Vascular Surgery with an emphasis on lower extremity revascularization procedures. He and his colleagues were the first to advocate an aggressive approach to saving limbs threatened by arteriosclerosis and gangrene when most patients with this problem were being treated by a major amputation.  In the late 1980s and early 1990s Dr. Veith became increasingly involved with endovascular treatments. He and his group were the first to perform an endovascular graft repair of an abdominal aortic aneurysm or EVAR in the United States. They also were the first in the world to perform an EVAR for a ruptured abdominal aneurysm. Dr. Veith has held positions in every national vascular society and many international ones. In 1995 he was elected President of the Society for Vascular Surgery, the most prestigious society in the field.  He has been a leading advocate for the recognition of Vascular Surgery as a separate and distinct specialty and is the past Chairman of the American Board of Vascular Surgery. Dr. Veith held positions as Chief of Vascular Surgery and Interim Chairman of Surgery at Montefiore Medical Center and Albert Einstein College of Medicine for many years. He was also The William J. Von Liebig Chair in Vascular Surgery and the Vice Chairman of the Department of Surgery.

Throughout his career he has received numerous awards and honors as a leader, outstanding teacher and innovator in Vascular Surgery.  He was Professor of Surgery and the William J. von Liebig Chair in Vascular Surgery at the Cleveland Clinic and Professor of Surgery at New York University Medical Center. As he has done for many years, Dr. Veith also Chairs the largest Vascular Surgery meeting, the VEITH symposium, held annually in New York City. In June of 2010, Dr. Veith received the SVS Distinguished Lifetime Achievement Award. In 2013 an endowed chair, the Frank J. Veith Chair in Vascular and Endovascular Surgery, was established at New York University Medical School to honor Dr. Veith. Also in 2013 Dr. Veith received the Lifetime Achievement Award of the Houston Aortic Symposium.